



ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2019 Operating Results

October 18, 2019

WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 18, 2019-- [ImmunoGen, Inc.](https://www.immunogen.com) (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, November 1, 2019 to discuss its third quarter operating results. Management will also provide a brief update on the business.

CONFERENCE CALL INFORMATION

To access the live call by phone, dial (877) 621-5803; the conference ID is 8865657. The call may also be accessed through the Investors and Media section of [immunogen.com](https://www.immunogen.com). Following the call, a replay will be available at the same location.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to "target a better now."

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20191018005041/en/>

Source: ImmunoGen, Inc.

INVESTOR RELATIONS AND MEDIA

ImmunoGen
Courtney O'Konek
781-895-0600
courtney.okonek@immunogen.com

OR

FTI Consulting
Robert Stanislaro
212-850-5657
robert.stanislaro@fticonsulting.com